epilepsy_drug_qol_df: SANAD Epilepsy Drug Treatment Quality of Life Study

In NeuroDataSets: A Comprehensive Collection of Neuroscience and Brain-Related Datasets

SANAD Epilepsy Drug Treatment Quality of Life Study

Description

This dataset, epilepsy_drug_qol_df, is a data frame containing quality of life measurements from the SANAD randomized controlled trial comparing carbamazepine and lamotrigine in 544 epilepsy patients. QoL assessments were collected at baseline, 3 months, 1 year and 2 years using validated instruments.

Usage

data(epilepsy_drug_qol_df)

Format

A data frame with 1,852 observations and 9 variables:

id

Integer: Patient identification number

with.time

Numeric: Time to withdrawal/discontinuation (days)

trt

Factor with 2 levels: Treatment group (carbamazepine/lamotrigine)

with.status

Integer: Withdrawal status indicator

time

Numeric: Assessment time point (days since baseline)

anxiety

Numeric: Anxiety score (from QoL measure)

depress

Numeric: Depression score (from QoL measure)

aep

Numeric: Adverse effects profile score

with.status2

Numeric: Alternative withdrawal coding

Details

The dataset name has been kept as 'epilepsy_drug_qol_df' to avoid confusion with other datasets in the R ecosystem. This naming convention helps distinguish this dataset as part of the NeuroDataSets package. The suffix 'df' indicates that the dataset is a data frame. The original content has not been modified.

Source

Data taken from the joineRML package version 0.4.7. Original study: Marson, A.G., et al. (2007) The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. The Lancet, 369(9566), 1000-1015.

NeuroDataSets documentation built on Aug. 23, 2026, 1:08 a.m.